VIVUS INC Form 8-K October 15, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 15, 2013

VIVUS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-33389 (Commission File Number)

94-3136179 (IRS Employer Identification No.)

351 EAST EVELYN AVENUE

MOUNTAIN VIEW, CA 94041


(Address of principal executive offices, including zip code)

(650) 934-5200

(Registrant s telephone number, including area code)

1	N	1	٨
	N	1	Н

(Former name or former address, if changed since last report)



Item 7.01. Regulation FD Disclosure

On October 15, 2013, VIVUS, Inc., or the Company, participated in meetings during which members of its senior management team discussed business highlights and events, corporate priorities, prescription data, the commercialization of Qsymia®, the European strategy for Qsiva , STENDRA /SPEDRA partnerships, and certain other information. A copy of the slides presented at the meetings is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act of 1934, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No. Description

99.1 Slide presentation entitled Innovative Therapies, Novel Products

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIVUS, INC.

/s/ John L. Slebir John L. Slebir Vice President, Business Development and General Counsel

Date: October 15, 2013

3

EXHIBIT INDEX

Number	Description
99.1	Slide presentation entitled Innovative Therapies, Novel Products
	4